C12Y 304/22031
Ananain
Official title: Ananain (3.4.22.31)
C12Y304/22031 (Ananain) appears on 5 US grants and 13 published applications in this corpus.
Search patents in C12Y- Granted patents
- 5
- Published applications
- 13
- Assignees
- 8
- Inventors
- 24
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2014 | 0 | 1 |
| 2015 | 0 | 0 |
| 2016 | 1 | 0 |
| 2017 | 0 | 1 |
| 2018 | 0 | 0 |
| 2019 | 1 | 2 |
| 2020 | 0 | 0 |
| 2021 | 0 | 0 |
| 2022 | 1 | 0 |
| 2023 | 0 | 2 |
| 2024 | 0 | 4 |
| 2025 | 0 | 2 |
| 2026 | 2 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Protease composition6 Oct 2026US 12,751,997 B2Anatara Lifesciences Limited
- Bromelain protease, bromelain, jacalin-like lectin, extract from the stem and/or the fruit of a pineapple plant, combination preparation, bromelain protease inhibitor, protein/protease mix, and glycated bromelain protein formed by exogenous non-enzymatic glycation, for use in the treatment or prophylaxis of virus infections caused by coronaviruses in a human or animal15 Sep 2026US 12,734,223 B2Helmholtz-Institut FüR Pharmazeutische Forschung Saarland
- Debriding composition for treating wounds12 Jul 2022US 11,382,958 B2MediWound Ltd.
- Proteolytic extract from bromelain for the treatment of connective tissue disorders21 May 2019US 10,293,033 B2MediWound Ltd.
- Proteolytic extract from bromelain for the treatment of connective tissue disorders6 Dec 2016US 9,511,126 B2MediWound Ltd.
- Method of producing collagen22 Jan 2026US 2026/0022159 A2Holista Colltech Limited
- Method of producing collagen17 Jul 2025US 2025/0230219 A2Holista Colltech Limited
- Methods for treating respiratory diseases9 Jan 2025US 2025/0009856 A1Mucpharm Pty Ltd
- Method of producing collagen21 Nov 2024US 2024/0383966 A1Holista Colltech Limited
- Bromelain protease, bromelain, jacalin-like lectin, extract from the stem and/or the fruit of a pineapple plant, combination preparation, bromelain protease inhibitor, protein/protease mix, and glycated bromelain protein formed by exogenous non-enzymatic glycation, for use in the treatment or prophylaxis of virus infections caused by coronaviruses in a human or animal4 Jul 2024US 2024/0216484 A1Helmholtz-Institut FüR Pharmazeutische Forschung Saarland
Most cited
By later US patents
No patent in this class has been cited by a later US patent yet.